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Immunity to Sand Fly Salivary Protein LJM11
Modulates Host Response to Vector-Transmitted
Leishmania Conferring Ulcer-Free Protection
Regis Gomes1, Fabiano Oliveira1, Clarissa Teixeira1, Claudio Meneses1, Dana C. Gilmore1,
Dia-Eldin Elnaiem2, Shaden Kamhawi1 and Jesus G. Valenzuela1
Leishmania vaccines that protect against needle challenge fail against the potency of a Leishmania-infected sand
fly transmission. Here, we demonstrate that intradermal immunization of mice with 500 ng of the sand fly
salivary recombinant protein LJM11 (rLJM11) from Lutzomyia longipalpis, in the absence of adjuvant, induces
long-lasting immunity that results in ulcer-free protection against Leishmania major delivered by vector bites.
This protection is antibody independent and abrogated by depletion of CD4þ T cells. Two weeks after
challenge, early induction of IFN-g specifically to rLJM11 correlates to diminished parasite replication in
protected animals. At this time point, Leishmania-specific induction of IFN-g in these mice is low in comparison
with its high level in non-protected controls. We hypothesize that early control of parasites in a T-cell helper
type 1 environment induced by immunity to LJM11 permits the slow development of Leishmania-specific
immunity in the absence of open ulcers. Leishmania-specific immunity observed 5 weeks after infection in
rLJM11-immunized mice shows a twofold increase over controls in the percentage of IFN-g-producing CD4þ
T cells. We propose LJM11 as an immunomodulator that drives an efficient and controlled protective immune
response to a sand fly–transmitted Leishmania somewhat mimicking ‘‘leishmanization’’-induced protective
immunity but without its associated lesions.
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INTRODUCTION
In vector-borne diseases, the contribution of vector saliva to
pathogen establishment in mammalian hosts is largely ignored.
Leishmania parasites are transmitted by phlebotomine sand
flies and present as a wide range of clinical etiologies including
visceral, mucocutaneous, diffuse, and cutaneous leishmaniasis
(CL) (WHO, 2010). Every time an infected sand fly takes a
blood meal, it deposits parasites and saliva into the skin. Sand
fly saliva is composed of biologically active proteins (Valen-
zuela et al., 2004). Importantly, certain salivary proteins are
immunogenic in different mammalian hosts, including humans
(Valenzuela et al., 2001; Oliveira et al., 2006, 2008; Gomes
et al., 2008; Collin et al., 2009; Teixeira et al., 2010).
In rodent models of infection, immunity to sand fly saliva or
salivary molecules confers protection against both cutaneous
and visceral leishmaniasis (Belkaid et al., 1998; Kamhawi
et al., 2000; Valenzuela et al., 2001; Gomes et al., 2008;
Oliveira et al., 2008; Collin et al., 2009). This protection
results from the close proximity of salivary molecules to
Leishmania at the site of an infective bite where immunity
to a salivary molecule can adversely impact the parasites.
Recently, it was shown that immunization with LJM11 DNA,
encoding a 43.2-kDa salivary protein from Lutzomyia long-
ipalpis, induced delayed-type hypersensitivity response in
mice and protected against needle challenge comprising
Leishmania major plus Lu. longipalpis saliva (Xu et al., 2011).
Despite accumulating evidence regarding the immuno-
genicity of sand fly saliva, two questions vital to the concept
of saliva-based vaccines remain unanswered. First, would
immunity to a sand fly salivary protein be powerful enough
against the virulence of vector-transmitted parasites (Rogers
et al., 2004, 2006; Peters et al., 2008, 2009)? And if so, what
are the immune correlates for this protection?
In this work, we demonstrate that adjuvantless immuniza-
tion with rLJM11 modulates the mammalian host immune
response to virulent vector-transmitted Leishmania parasites,
resulting in ulcer-free protection against CL and establishing a
vital role for CD4þ T cells in LJM11-mediated protection.
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RESULTS
Immunization with the recombinant salivary protein LJM11
(rLJM11) in the absence of adjuvant drives a robust T-cell helper
type 1 (Th1) immune response
We produced rLJM11 in 293-HEK cells and purified it by
high-pressure liquid chromatography (Figure 1a). The protein
was soluble and had low endotoxin levels. Two weeks after
the last immunization with 500 ng of rLJM11 in the absence
of adjuvant, serum from rLJM11-immunized mice showed
high levels of total IgG specific to rLJM11 with a high
IgG2a:IgG1 ratio (Figure 1b). A robust rLJM11-specific
cellular immune response characterized by IFN-g production
was observed upon in vitro stimulation of lymph nodes (LNs)
and spleen cells with 20 mg of rLJM11 (Figure 1c and d).
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Figure 1. Immunity generated by recombinant LJM11 salivary protein (rLJM11) is polarized toward a T-cell helper type 1 (Th1) response. (a) High-pressure
liquid chromatography (HPLC) purification of rLJM11 (k). Inset: silver-stained gel of purified rLJM11. (b–f) C57BL/6 mice were immunized with 500 ng of either
rLJM11 or BSA in the left ear. (b) Total IgG levels against rLJM11 and the IgG2a:IgG1 ratio. IFN-g, IL-10, and IL-4 production following in vitro stimulation of
lymph node (LN, c) and (d) spleen cells with rLJM11. (e) Delayed-type hypersensitivity (DTH) response in mice immunized with rLJM11 (’) or BSA (K). (f) The
absolute number of CD4þ T cells per ear following sand fly challenge. *Po0.05; **Po0.01; ***Po0.001. Data are representative of three independent
experiments (n¼ 5). ND, not detected.
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Following 3 days of stimulation with rLJM11, 371 and
1263pgml–1 of IFN-g was produced by LN and spleen cells of
immunized mice, respectively; IL-10 was also induced at a
lower level, with 257 and 318pgml–1 detected from LNs and
spleen cells, respectively; IL-4 was only detected from spleen
cells (Figure 1d). Furthermore, exposure of rLJM11-immu-
nized mice to uninfected sand fly bites showed a 4.5-fold
increase (Po0.05) in differential ear thickness compared with
the BSA-immunized group 48 hours after bite (Figure 1e).
Recovery of cells from mouse ears revealed a 2.7-fold greater
number of CD4þ T cells at the bite site of rLJM11-immunized
mice compared with BSA-immunized animals (Figure 1f).
Immunity generated by rLJM11 confers ulcer-free protection
against Leishmania transmitted by sand fly bites
Two weeks after challenge with L. major–infected Lu.
longipalpis sand flies, mice immunized with rLJM11 con-
trolled the infection, maintaining a significantly smaller
number of parasites in LNs (Po0.01) and ears (Po0.05)
compared with the BSA-immunized group (Figure 2a). The
lower number of parasites correlated with the absence of
lesions in rLJM11-immunized mice compared with BSA-
immunized animals (Figure 2a, panel). On stimulation with
rLJM11, LN cells recovered from rLJM11-immunized mice 2
weeks after challenge showed a significant increase in IFN-g
production (Po0.05) compared with BSA-immunized ani-
mals (Figure 2b), indicative of a specific Th1 cellular immune
response to the salivary protein. IL-4 was not detected
following stimulation with rLJM11 in either rLJM11-immu-
nized or control mice. Surprisingly, when LN cells were
stimulated with soluble Leishmania antigen to test for specific
parasite immune responses, we observed a greater amount of
IFN-g in BSA-immunized mice compared with rLJM11-
immunized mice—the group that controlled parasite infec-
tion (Figure 2b). No significant differences were observed for
IL-10 between these two groups, but IL-4 levels were greater
(although in relatively small amounts) in BSA-immunized
animals compared with rLJM11-immunized animals (Figure
2b). Protection in rLJM11-immunized mice was maintained
up to 5 weeks after challenge (Figure 2c), when the study had
to be terminated owing to extensive lesions observed in ears
of the BSA-immunized group (Figure 2d, panel). Furthermore,
the number of parasites was significantly lower in the LNs
(Po0.001) and ears (Po0.01) of rLJM11-immunized mice
compared with BSA-immunized mice 5 weeks after chal-
lenge (Figure 2d). It is important to note that the number of
parasites detected in rLJM11-immunized mice, although
considerable, did not manifest as open ulcers where none
of the animals showed lesions throughout the follow-up
period (Figure 3d, panel).
Immunization with rLJM11 protects B-cell/ mice against
L. major–infected sand fly bites
To determine the importance of antibodies to LJM11-
mediated protection, we challenged B-cell–deficient mice
(B-cell/ mice) immunized with either rLJM11 or BSA with
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Figure 2. Immunization with rLJM11 protects mice against Leishmania major–infected Lutzomyia longipalpis vector challenge. (a) Parasite load from
lymph nodes (LNs) or ears of rLJM11- or BSA-immunized mice 2 weeks after sand fly challenge. Panel: cutaneous lesions at this time point. (b) ELISA
measurements of IFN-g, IL-10, and IL-4 from LN cells of BSA- or rLJM11-immunized mice after stimulation with soluble Leishmania antigen (SLA) or rLJM11.
(c) Lesion thickness in animals immunized with rLJM11 (’) or BSA (K) following challenge with 10 infected sand flies. (d) Parasite load 5 weeks after
infected sand fly challenge in the LN and ears of BSA- or rLJM11-immunized mice. *Po0.05; **Po0.01; ***Po0.001. Cumulative data of two independent
experiments are shown (n¼ 5). ND, not detected.
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L. major–infected Lu. longipalpis sand flies. As expected,
B-cell/mice did not generate antibodies following immuni-
zation with rLJM11 (Figure 3a). Furthermore, rLJM11-
immunized mice maintained the ability to induce a cellular
immune response comparable to that of wild-type rLJM11-
immunized mice demonstrated by a 3.2-fold increase
(Po0.001) in differential ear thickness compared with BSA-
immunized B-cell/ mice 48 hours after challenge with
infected sand flies (Figure 3b). Importantly, rLJM11-immu-
nized B-cell/ mice controlled L. major infection at the
same magnitude as wild-type rLJM11-immunized mice
(Figure 3c). It is noteworthy that ears of rLJM11-immunized
B-cell/ mice were intact, with no tissue damage compared
with those of the B-cell/ BSA- or wild-type BSA-immunized
groups, which presented typical CL lesions (data not shown).
These data establish that antibodies are not required for
LJM11-induced protection against vector-transmitted CL.
Depletion of CD4þ T cells abrogates protection from L. major
conferred by immunity to rLJM11
To determine the importance of CD4þ T cells in rLJM11-
induced protection, we depleted CD4þ T cells from rLJM11-
immunized mice 2 days before sand fly transmission and on a
weekly basis thereafter. CD4þ T cells were absent from
depleted mice as demonstrated at 48 hours and 1 week after
exposure to L. major–infected Lu. longipalpis bites (Figure
4a). It is noteworthy that CD8þ T cells were unaffected by
depletion of CD4þ T cells (Figure 4a). Following challenge
with L. major–infected Lu. longipalpis, animals immunized
with rLJM11 and treated with a control isotype antibody
controlled the infection throughout the follow-up period
(Figure 4b). In contrast, the protection was lost in rLJM11-
immunized animals treated with anti-CD4 antibody, produ-
cing a disease outcome similar to that in animals immunized
with BSA (Figure 4b).
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Figure 3. LJM11 immunization protects B-cell/mice against infected sand fly challenge. B-cell/ and wild-type (WT) mice were immunized with rLJM11 or
BSA in the left ear. (a) Western blot against rLJM11 in rLJM11-immunized mice. (b, c) Mice challenged with infected flies in the right ear 2 weeks after
immunization. (b) Delayed-type hypersensitivity (DTH) response 48 hours after challenge in rLJM11-immunized WT (’) or B-cell/ (m) mice and in BSA-
immunized WT (K) or B-cell/ (.) mice. (c) Lesion thickness in rLJM11-immunized WT (’) or B-cell/ (m) mice and BSA-immunized WT (K) or B-cell/
(.) mice. *Po0.05; **Po0.01; ***Po0.001. Data are representative of two independent experiments (n¼5).
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Figure 4. Depletion of CD4þ T cells abrogates protection from sand fly–transmitted Leishmania in rLJM11-immunized mice. Mice were immunized
with rLJM11 or BSA in the left ear. Forty-eight hours before infected challenge and weekly thereafter, rLJM11-immunized mice were treated with anti-CD4
(GK 1.5) or isotype (IgG2b). (a) CD4þ and CD8þ T cells in peripheral blood 48 hours and 1 week following challenge with infected sand flies. The frequency
of cells is indicated on the corners of contour plots. (b) Lesion size of animals immunized with rLJM11 and treated with anti-CD4 (m) or isotype (’) and in
BSA-immunized mice (K). *Po0.05; **Po0.01; ***Po0.001. Representative (a) and cumulative (b) data are shown (n¼ 5).
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Adjuvantless immunization with rLJM11 generates
long-term immunity that protects mice against challenge
by L. major–infected Lu. longipalpis sand flies
To investigate the capacity of rLJM11 to generate long-term
immunity, we evaluated the status of the immune response 5
months after the last immunization. LJM11-specific IgG
antibody response was sustained in rLJM11-immunized mice
(Figure 5a and b) and maintained a high IgG2a:IgG1 ratio
(Figure 5b). More important was the fact that the cellular
immune response of rLJM11-immunized mice was not
compromised 5 months after the last immunization (Figure
5c). Examination of histologic sections of mouse ears 48
hours following challenge with infected flies showed an
increase in ear thickness of rLJM11-immunized mice
compared with BSA controls. A distinct cellular recruitment
with intense lymphocytic infiltration characteristic of a
delayed-type hypersensitivity response was observed at the
bite site in rLJM11-immunized mice (Figure 5d). Cells
recovered ex vivo from the site of bite in rLJM11-immunized
mice showed a considerable increase in the frequency of
CD4þ T cells producing either IFN-g alone (single producers)
or both IFN-g and tumor necrosis factor-a (double producers)
compared with controls (Figure 5e). The salient question
remains whether long-term memory to rLJM11 is robust
enough to confer protection against vector-transmitted CL.
Figure 5f shows that rLJM11-immunized mice challenged
with L. major–infected Lu. longipalpis sand flies 5 months
after the last immunization display a solid protection from
disease throughout the study period. Furthermore, the
number of parasites 5 weeks after infection was significantly
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Figure 5. rLJM11 immunization induces protective long-lasting immunity against vector-transmitted Leishmania. Mice were immunized with rLJM11 (’) or
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(H&E)-stained ear sections (400 ). (e) Absolute number of CD4þ T cells per ear producing IFN-g and tumor necrosis factor (TNF)-a 48 hours after challenge.
(f) Lesion thickness. (g) Parasite load 5 weeks after challenge. (h) Frequency of CD4þ IFN-gþ cells 5 weeks after stimulation with soluble Leishmania antigen
(SLA). ***Po0.001; **Po0.01; *Po0.05. Data are representative of two independent experiments (n¼5).
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lower in ears of rLJM11-immunized mice, showing over
a 3-log reduction (Po0.01) compared with the BSA-
immunized group (Figure 5g). In addition, when cells
were recovered from infected ears 5 weeks after infection
and stimulated with soluble Leishmania antigen, 16% of
CD4þ T cells produced IFN-g in rLJM11-immunized mice
compared with only 6% in control mice (Figure 5h). These
data suggest that following exposure to parasites, rLJM11-
immunized animals develop Leishmania-specific immunity
in the absence of ulcers.
DISCUSSION
A vaccine that protects mice against needle challenge
of L. major fails when challenged by sand fly–transmitted
parasites (Rogers et al., 2004, 2006; Peters et al., 2009).
This highlights the virulence of vector-initiated Leishmania
infections and the need to identify new approaches or
antigens to combat this neglected disease (Rogers et al.,
2004, 2006; Bethony et al., 2011). Here, we demonstrate
that immunization with a defined salivary protein from
Lu. longipalpis, LJM11, in the absence of adjuvant modulates
the host immune response to Leishmania parasites,
resulting in protection against challenge with infected sand
flies.
Throughout the study, we used a recent field isolate of
L. major transmitted by vector bites, a highly virulent
challenge. This highlights both the potency of the protection
observed in rLJM11-immunized mice and the unusual
severity of lesions in control groups. The potency of rLJM11
immunity is underscored by ulcer-free protection from CL
observed in mice challenged up to 5 months following the
last immunization. As a result of the lesion severity in control
groups, mice were killed 5 weeks after infection. At this time
point, live parasites were still observed in rLJM11-immunized
mice despite the absence of ulcers. Further studies with
longer follow-up periods are needed to assess the duration of
LJM11-mediated protection from CL. Reassuringly, mice
vaccinated with complementary DNA encoding LJM11 and
challenged by needle injection of parasite were protected up
to 12 weeks after infection (Xu et al., 2011). Although
immunization with rLJM11 may not mimic the outcome of
vaccination with LJM11 DNA, we previously demonstrated
that immunization with the sand fly salivary gland homo-
genate, in which the dominant Th1-inducing protein is
LJM11, in the absence of adjuvant, produced a sustained
protection against CL 12 weeks after challenge (Xu et al.,
2011). This argues in favor of long-lasting immunity by
rLJM11-induced immunity in the absence of adjuvant.
The cornerstone of LJM11-mediated immunity is cellular,
where CD4þT cells producing IFN-g or both IFN-g and
tumor necrosis factor-a were prominent in the ears and
draining LN of rLJM11-immunized mice challenged with
infected sand flies. Induction of multifunctional T cells that
have been implicated in enhanced immunity to CL (Darrah
et al., 2007) further emphasizes the significance of anti-saliva
immunity in protection from leishmaniasis. The vital role of
CD4þ T cells in LJM11-mediated protection is underlined by
the abrogation of protection on depletion of these cells.
Despite the fact that we cannot distinguish saliva-specific
from Leishmania-specific CD4þ T cells in this study, we can
conclude that the mechanism of saliva-mediated protection is
not independent from CD4þ T cells. If anything, this finding
suggests that saliva-mediated protection is intricately con-
nected to the development of Leishmania-specific immunity.
It is noteworthy that in the absence of CD4þ T cells CD8þ
T cells do not have a major role in saliva-mediated protection
from CL. Furthermore, antibodies are not required, suggesting
that the protective effect is not related to antibody neutraliza-
tion of LJM11.
Importantly, this protection was observed following
immunization with a small amount (500 ng) of rLJM11 in
the absence of adjuvant. LJM11 belongs to the Yellow family
of proteins found exclusively in insects and only from sand fly
saliva in its secreted form. The crystal structure of LJM11
displays a strong positive charge on one of its surfaces
(Xu et al., 2011). The induction of long-term immunity
by this protein in the absence of adjuvant is remarkable
and represents an important feature in its consideration
as a vaccine candidate. Part of the immunogenicity
of this molecule may be due to its exclusive presence in
sand fly saliva, making it quite foreign to the mammalian
immune system. In addition, this molecule may be acting
as a self-adjuvanting protein via its positively charged
face that may promote interaction with cells of the innate
immune system.
BSA-immunized mice challenged 2 weeks after the last
immunization showed severe lesions that contained a large
number of viable parasites despite the presence of a high
level of Leishmania-specific IFN-g. The failure to control CL
in the presence of such an elevated level of IFN-g remains
unexplained particularly in light of the low level of detectable
IL-4. We cannot fully exclude the fact that the observed low
levels of IL-4 may have contributed to disease progression.
Alternatively, other regulatory molecules could be protecting
the parasite and promoting disease. In comparison, the ulcer-
free protection resulting from immunity to LJM11 in mice
challenged 2 weeks after the last immunization is striking.
The immune response in LNs 2 weeks after infection in these
mice reflects a Th1 environment characterized by the
induction of LJM11-specific IFN-g in the absence of IL-4.
We believe that, in contrast to the BSA group, parasite
replication is controlled in rLJM11-immunized mice by a
moderate induction of LJM11-specific IFN-g. In a
separate experiment, rLJM11-immunized mice challenged
5 months after the last vaccination maintained powerful
protection from CL. Importantly, these mice demonstrated a
robust Leishmania-specific immunity 5 weeks after infection.
This is important for long-lasting protection of rLJM11-
immunized mice.
Leishmanization—the inoculation of virulent parasites—
results in strong and durable immunity (Handman, 2001).
This involves the development of patent disease at the chosen
site of inoculation followed by cure. Leishmanization was
discontinued owing to several factors, including the devel-
opment of adverse reactions in a proportion of ‘‘leishma-
nized’’ individuals and lack of reproducibility (Handman,
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2001). Thus far, leishmanization, the gold standard for
protection in humans, is represented by mice that have
healed their lesions (Peters et al., 2009). Immunization with
rLJM11 provides a better alternative in which rLJM11-
immunized mice challenged by vector transmission of
virulent L. major develop Leishmania-specific immunity
characterized by persistence of live parasites in the absence
of CL lesions.
In conclusion, this work reveals several new aspects
pertinent to understanding the potency and mechanism of
sand fly saliva–mediated protection from leishmaniasis. We
demonstrate that (i) immunity to a single salivary molecule
confers protection against vector-transmitted CL; (ii) adju-
vantless immunity generated by such a molecule is long
lasting, conferring undiminished protection in mice chal-
lenged 5 months after the last immunization; (iii) protection
from CL as a result of saliva-induced immunity is cell
mediated and dependent on CD4þ T cells; and (iv) anti-
saliva immunity leads to the development of a controlled
ulcer-free Leishmania-specific immunity.
MATERIALS AND METHODS
Animals
C57BL/6 mice were from Charles River Laboratories (Wilmington,
MA). B-cell–deficient [B/](B10.129S2(B6)-Igh-6/tm1CgnS/j mice)
were from Jackson Laboratory (Bar Harbor, ME).
Ethics statement
All animal procedures were reviewed and approved by the National
Institute of Allergy and Infectious Diseases (NIAID) Animal Care and
Use Committee.
Sand flies and preparation of salivary gland homogenate
Lu. longipalpis sand flies, Jacobina strain, were reared at the
Laboratory of Malaria and Vector Research, NIAID, NIH. Salivary
glands were dissected from 5- to 7-day-old females and stored in
phosphate-buffered saline at 70 1C. Salivary glands were sonicated
and centrifuged at 12,000 g for 3 minutes.
Parasites
L. major promastigotes (WR 2885 strain) were cultured in
Schneider’s medium supplemented with 20% heat-inactivated fetal
bovine serum, 2mM L-glutamine, 100Uml–1 penicillin, and
100ml ml–1 streptomycin. WR 2885 strain was typed at the Walter
Reed Army Institute of Research.
Production and purification of recombinant LJM11 protein
(rLJM11)
LJM11 DNA plasmids with a histidine tag were sent to the Protein
Expression Laboratory at NCI-Frederick (Frederick, MD) for expres-
sion in HEK-293F cells. Expressed protein was purified as previously
described (Collin et al., 2009) and by using a GS2000SW molecular
sieving column connected to a Dionex high-pressure liquid
chromatography pump (Thermo Fischer Scientific, Waltham, MA).
The protein was eluted using phosphate-buffered saline, pH 7.2, at
1mlmin–1 and detected at 280 nm. Purity of the eluted rLJM11 was
verified by separation on a 4–12% NuPAGE gel followed by silver
staining using SilverQuest (Life Technologies, Grand Island, NY).
The endotoxin level of the recombinant protein was measured using
the ToxinSensor Chromogenic LAL endotoxin assay kit (GenScript,
Piscataway, NJ). The endotoxin level of used rLJM11 batches was
below 20 EUml–1.
Exposure of mice to uninfected sand flies
Female flies (5–7 days old) were starved of sugar overnight and
placed in plastic vials covered at one end with a 0.25-mm nylon
mesh. Mice exposure was performed as previously described
(Kamhawi et al., 2000).
Immunization of mice
Mice were immunized intradermally in the left ear, three times at
2-week intervals, with 10 ml containing 500 ng of either rLJM11
(without adjuvant) or BSA in phosphate-buffered saline.
Sand fly infection and transmission of L. major to vaccinated
mice
Procyclic parasites were washed with phosphate-buffered saline,
centrifuged at 3,500 r.p.m. for 15 minutes, and counted. Infection of
sand flies with Leishmania (3 106ml–1) was performed as described
previously (Kamhawi et al., 2000). The sand flies were used for
transmission on days 12 or 13 after infection.
Measurement of the delayed-type hypersensitivity response and
lesion size
Measurements were obtained using a Vernier caliper (Mitutoyo,
Baltimore, MD). For delayed-type hypersensitivity responses, the
differential ear thickness for each group of mice was measured from
values of the mean ear thickness 48 hours after exposure to sand fly
bites subtracted from the mean ear thickness of the same mice before
exposure; for Leishmania lesions, the largest thickness of an ear
lesion was recorded.
Histologic analysis
Mouse ears were fixed in 10% phosphate-buffered formalin and
embedded in paraffin. Sections (5mm) were stained with hematox-
ylin–eosin at Histoserv (Germantown, MD)
ELISA
ELISA plates (Immulon4-Thermo, Waltham, MA) were coated
overnight at 4 1C with 2mgml–1 rLJM11. After washing and blocking
with 4% BSA for 2 hours at room temperature, sera from immunized
mice (1:50) were incubated for 1 hour at 37 1C. After washing, plates
were incubated with alkaline phosphatase–conjugated anti-mouse
IgG (Promega, Madison, WI), IgG1 (BD Biosciences, Sparks, MD), or
IgG2a (BD Biosciences) antibody (1/1,000). The reaction was
revealed using alkaline phosphate substrate (Promega). Absorbance
was recorded at 405 nm.
Western blot analysis
Western blot analysis for rLJM11 (10 mg) was performed as previously
described (Valenzuela et al., 2001).
Ear tissue preparation
Ear tissue was processed as previously described (Belkaid et al.,
1998; Peters et al., 2009). For ex vivo experiments, 2 million cells
were cultured for 4 hours with Brefeldin A (BD Golgi Plug; BD
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Pharmingen, Sparks, MD). For experiments involving overnight
stimulation, 2 million cells were cultured with bone marrow–
derived dendritic cells generated as previously described (Lutz et al.,
1999) with or without Lu. longipalpis salivary gland homogenate
(2 pairml–1), rLJM11 (4mgml–1), or soluble Leishmania antigen
(100mgml–1) at 37 1C and 5% CO2 for 18 hours. Brefeldin A was
added during the last 4 hours of culture. Cell were then harvested
and analyzed by flow cytometry.
Parasite quantification by limiting dilution assay
Parasite quantification was performed as previously described (Titus
et al., 1985; Belkaid et al., 1998).
Flow cytometry
The following antibodies were used for cell staining: PerCP or
FITC-labeled anti-CD4 (RM4-5 and GK1.5), PerCP-labeled anti-CD8
(53-6.7), antigen-presenting cell-labeled anti-TCR-b (H57-597),
FITC-labeled anti-IFN-g (XMG 1.2), and phycoerythrin-labeled
anti-tumor necrosis factor-a (MP6-XT22). A minimum of 100,000 cells
were acquired using a FACSCalibur cytometer (BD Biosciences). Data
were analyzed with the Flow Jo software version 9.4.10 (Tree Star,
Phoenix, AZ).
In vitro stimulation of LN cells with rLJM11-pulsed bone
marrow–derived dendritic cells
At day 6, cultured bone marrow–derived dendritic cells were pulsed
overnight with 10 mgml–1 of rLJM11. The next day, pulsed and naive
bone marrow–derived dendritic cells were cultured in the presence
of LN cells from mice immunized with rLJM11 or from naive cells.
Cells were incubated at 37 1C with 5% CO2. Supernatants were
collected and analyzed by ELISA.
In vitro stimulation of spleen cells with rLJM11
Spleen cells (5 106ml–1) were cultured in RPMI medium
(Life Technologies) supplemented with 10% heat-inactivated
fetal bovine serum, 100Uml–1 of penicillin, 100mgml–1 of strepto-
mycin, and 5 105 M of 2-mercaptoethanol (Sigma, St. Louis, MO)
in the presence of 20 mgml–1 of rLJM11. Cells were incubated at
37 1C with 5% CO2 for 72 hours. Supernatants were collected and
analyzed by ELISA.
Cytokine ELISA
LN and spleen cells from rLJM11-immunized mice or naive mice
were processed as mentioned above. After 72 hours of stimulation
with rLJM11, IFN-g, IL-10, and IL-4 levels were measured in
supernatants using specific sandwich ELISA (BD Biosciences).
CD4þ T-cell depletion
Mice were injected intraperitoneally with 0.5mg of anti-mouse CD4
(L3T4) mAb (GK 1.5 clone) or rat anti-mouse IgG2b isotype, both
from eBioscience (San Diego, CA), 2 days before challenge and
weekly until the end of the experiment.
Statistical analysis
The Student’s two-tailed unpaired t-test was used for statistical
analysis between two groups. Multiple groups were analyzed using
one-way analysis of variance followed by Tukey’s multiple-
comparison test.
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